OXNARD, Calif.--(enterprise WIRE)--Jan 5, 2021--
remedy Pharmaceutical conserving Corp. ("remedy" or the "enterprise") (OTC: CURR), a expertise concentrated, vertically integrated drug start and product building enterprise within the pharmaceutical and fitness & wellbeing house, introduced today that the U.S. meals and Drug Administration (FDA) has approved an Investigational New Drug (IND) utility for its product CUREfilm Blue™, an oral soluble film of sildenafil citrate (the lively ingredient existing in Viagra® 1 ) for the treatment of erectile dysfunction (ED). remedy is seeking approval of this product by means of the 505(b)(2) regulatory pathway to expedite the U.S. approval manner.
CUREfilm Blue™ makes use of the enterprise's patented and proprietary quickly-dissolving drug start platform, known as CUREfilm™, to convey the energetic pharmaceutical ingredient (API) sildenafil citrate. with the aid of innovating past the average pharmaceutical delivery of capsules and options, remedy is advancing this uniquely discrete, handy and transportable oral film product for reaching a stronger patient event.
"given that remedy changed into headquartered, moving our flagship know-how CUREfilm™ in the course of the FDA regulatory manner has been on the cornerstone of our pharmaceutical approach. This approval of the IND filing from the FDA marks a big milestone for our enterprise, validating the cost-proposition of our expertise and proprietary dosage kind," observed treatment CEO Rob Davidson. "Our oral movie expertise makes finished sense to meet patients' sildenafil needs for treating ED. Our team has labored diligently for the past yr to make several inroads on clinical efforts to obtain this vital accomplishment and i am assured that we're optimally positioned to proceed to trials in early 2021."
"The erectile dysfunction market has advanced drastically over the ultimate a few years with the introduction of telemedicine. Our patent pending CUREfilm Blue™ oral soluble film of sildenafil citrate may still bring a big price proposition to sufferers, physicians and suppliers within the erectile dysfunction market," spoke of cure Chief company Officer, Jonathan Berlent.
The global erectile dysfunction drug market is projected to attain approximately USD$6.6 Billion by using 2025, at a CAGR of 6.0% over the 5-year forecasted period with sildenafil representing a majority of the market in accordance with a record by means of QYR research.
About treatment Pharmaceutical retaining Corp.
cure Pharmaceutical ® is the pioneering developer of CUREform™, a patented drug start platform that offers a few interesting instant- and controlled-release drug beginning automobiles designed to improve drug efficacy, protection, and patient journey for a wide range of lively elements.
As a vertically integrated enterprise, remedy's 25,000 square foot, FDA-registered, NSF ® and cGMP-certified manufacturing facility allows for it to associate with pharmaceutical and health businesses global for personal and white-labeled construction. treatment has partnerships within the U.S., China, Mexico, Canada, Israel, and different markets in Europe.
1 Viagra ® is a registered trademark of Pfizer Inc.
ahead looking observation
Statements treatment makes in this press release can also encompass statements which aren't ancient data and are considered forward-looking inside the which means of section 27A of the Securities Act of 1933, as amended ("Securities Act"), and area 21E of the Securities change Act of 1934, as amended ("exchange Act"), which can be always identified by the use of phrases reminiscent of "anticipates," "believes," "estimates," "expects," "intends," "may additionally," "plans," "projects," "seeks," "should," "will," and adaptations of such phrases or similar expressions. remedy intends these ahead-searching statements to be covered by means of the secure harbor provisions for forward-looking statements contained in section 27A of the Securities Act and section 21E of the trade Act and is making this remark for applications of complying with these secure harbor provisions. These ahead-searching statements include, devoid of difficulty, the skill to effectively market the partnered items, the difficulty in predicting the timing or outcomes of connected research and construction efforts, partnered product characteristics and signs, advertising and marketing approvals and launches of different products, the impact of pharmaceutical business regulation, the have an effect on of competitive items and pricing, the acceptance and demand of latest pharmaceutical products, the affect of patents and different proprietary rights held by way of rivals and different third parties and the skill to gain financing on favorable terms. The forward-searching statements in this press unencumber mirror treatment's judgment as of the date of this press liberate. remedy disclaims any intent or responsibility to replace these ahead-looking statements. This press liberate shall now not represent a proposal to sell or the solicitation of a proposal to buy nor shall there be any sale of our securities in any state or jurisdiction by which such offer, solicitation or sale would be unlawful previous to registration or qualification beneath the securities laws of any such state or jurisdiction.
View source edition on businesswire.com:https://www.businesswire.com/information/home/20210105005370/en/
CONTACT: Licensing Contact:
Jonathan Berlent
Chief company Officer
remedy Pharmaceutical
Jberlent@curepharma.com
516.660.9148
investment Contact:
Gary Zwetchkenbaum
Plum Tree Consulting LLC
gzplumtree@gmail.com
516.455.7662
Media Contact:
Kathryn Brown
CMW Media
treatment@cmwmedia.com
858.264.6600
key phrase: CALIFORNIA united states NORTH the united states
business keyword: BIOTECHNOLOGY FDA PHARMACEUTICAL fitness
source: cure Pharmaceutical holding Corp.
Copyright company Wire 2021.
PUB: 01/05/2021 08:00 AM/DISC: 01/05/2021 08:01 AM
http://www.businesswire.com/information/domestic/20210105005370/en
0 Comments